Aiming to Achieve Mid-term Business Plan “IBI 18”
- 2017 Results and 2018 Outlook -

CHUGAI PHARMACEUTICAL CO., LTD.
President, COO
Tatsuro Kosaka

February 1/2, 2018
Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

Note: Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
2017 Results

Achieved record-high revenues and operating profit in the 15th anniversary year of the Strategic Alliance with Roche
## 2017 Financial Performance

Strong growth in revenues and operating profit mainly due to increase in exports/ROOI driven by global expansion of Alecensa and Actemra

<table>
<thead>
<tr>
<th>billion JPY</th>
<th>2016 Jan -Dec actual</th>
<th>2017 Jan - Dec actual</th>
<th>Growth</th>
<th>2017 Jan - Dec forecast</th>
<th>achiev. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>491.8</td>
<td>534.2</td>
<td>+42.4</td>
<td>+8.6%</td>
<td>520.5</td>
</tr>
<tr>
<td>Sales</td>
<td>472.7</td>
<td>499.3</td>
<td>+26.6</td>
<td>+5.6%</td>
<td>490.4</td>
</tr>
<tr>
<td>excl. Tamiflu</td>
<td>459.2</td>
<td>482.4</td>
<td>+23.2</td>
<td>+5.1%</td>
<td>482.2</td>
</tr>
<tr>
<td>Domestic</td>
<td>379.7</td>
<td>388.4</td>
<td>+8.7</td>
<td>+2.3%</td>
<td>393.9</td>
</tr>
<tr>
<td>Overseas</td>
<td>79.5</td>
<td>94.0</td>
<td>+14.5</td>
<td>+18.2%</td>
<td>88.4</td>
</tr>
<tr>
<td>Tamiflu</td>
<td>13.5</td>
<td>16.9</td>
<td>+3.4</td>
<td>+25.2%</td>
<td>8.2</td>
</tr>
<tr>
<td>Royalties and other operating income (ROOI)</td>
<td>19.1</td>
<td>34.9</td>
<td>+15.8</td>
<td>+82.7%</td>
<td>30.0</td>
</tr>
<tr>
<td><strong>Core Operating Profit</strong></td>
<td><strong>80.6</strong></td>
<td><strong>103.2</strong></td>
<td><strong>+22.6</strong></td>
<td><strong>+28.0%</strong></td>
<td><strong>92.0</strong></td>
</tr>
<tr>
<td><strong>Core EPS (yen)</strong></td>
<td><strong>102.50</strong></td>
<td><strong>138.68</strong></td>
<td><strong>+36.18</strong></td>
<td><strong>+35.3%</strong></td>
<td><strong>124.11</strong></td>
</tr>
</tbody>
</table>
Achievements in 2017

- emicizumab: US approval/launch for HA with inhibitors to FVIII
- Alecensa: EU launch, 1st line NSCLC approval in EU and US
- Regulatory filing for five projects
  - emicizumab (US/EU/Japan simultaneous filing for HA with inhibitors)
  - Alecensa (1st line NSCLC in EU/US), Tecentriq (2nd line NSCLC)
  - obinutuzumab (follicular lymphoma), Perjeta (adjuvant breast cancer)
- Established a new system to provide solutions initiated through collaboration of three divisions
- Divestment of 13 long-term listed products

Steady progress in key subjects towards the final year of IBI 18

HA: hemophilia A
NSCLC: non-small cell lung cancer
Emicizumab: Clinical Data to Support Global Rollout

- 2015
- 2016
- 2017
- 2018 -

Phase 1: Healthy adults and patients
→ Phase 1/2 (extension study): Patients

Non-interventional study: Patients
(Main purpose: real-world treatment data)

HAVEN 1
Phase 3: Inhibitor (adults and adolescents)
QW dosage

primary endpoint achieved

HAVEN 2
Phase 3: Inhibitor (children)
QW dosage

Apr. 2017
positive interim results

HAVEN 3
Phase 3: Non-inhibitor
QW and Q2W dosage

Nov. 2017
primary endpoint achieved

HAVEN 4
Phase 3: Non-inhibitor / Inhibitor
Q4W dosage

Dec. 2017
positive interim results

QW: dosing every week
Q2W: dosing every 2 weeks
Q4W: dosing every 4 weeks

Transfer of eligible patients

Phase 1 and 1/2: Japanese trials
Others: global trials with Roche
# Priority Agenda of IBI 18

- **Acquisition and implementation of competitiveness at a top global level**
- **Selection and Concentration strategy for acceleration of growth**

## Drug Discovery
- Continuous creation of engineered antibody projects
- Establishment of drug discovery technologies for middle molecules
- Research base for oncology/immunology

## Development
- emicizumab, atezolizumab
- Realization of early PoC with TCR
- Proof process for medical/economic value

## Pharmaceutical Technology
- Enhancement of CMC development infrastructure for early PoC acquisition
- Strengthening competitive advantages from late development to initial commercial production
- QA, QC and Regulatory functions

## Sales/Medical Affaires/Safety
- Growth driver products, emicizumab, atezolizumab
- Providing advanced solutions through a cross-functional system
- Establishment of system adapted to local characteristics

## Whole Company
- Acquisition, development and assignment of global top-class talents to lead value creation activities through innovation

- Expansion of achievements through selection and concentration utilizing **competitive advantage**
- Strengthening competitive foundation for global top-class level
Progress of IBI 18

- Cutting-edge immunology research in comprehensive collaboration with IFReC
- Initiated clinical trials for two in-house engineered antibody projects
- Advancement in middle-molecule drug discovery research

- Emicizumab trilateral regulatory filing (US, EU and Japan) and US approval
- Progress of atezolizumab development in multiple cancer types and approval in 2nd line NSCLC

- Progress in construction of high-mix low-volume production site for antibody API
- Completion of FDA pre-license inspection for emicizumab and enhancement of QC, QA, regulatory system for global supply

Established foundation to acquire and implement competitiveness at a top global level
2018 Outlook

Final year of “IBI 18”
Deliver expanded achievements as a culmination of three years

Core EPS CAGR* (2015-18) forecast: **9.5%**

<table>
<thead>
<tr>
<th></th>
<th>2017 Jan - Dec actual</th>
<th>2018 Jan - Dec forecast</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>534.2</td>
<td>541.5</td>
<td>+7.3</td>
</tr>
<tr>
<td><strong>Sales</strong></td>
<td>499.3</td>
<td>498.5</td>
<td>-0.8</td>
</tr>
<tr>
<td>excl. Tamiflu</td>
<td>482.4</td>
<td>492.9</td>
<td>+10.5</td>
</tr>
<tr>
<td>Domestic</td>
<td>388.4</td>
<td>374.8</td>
<td>-13.6</td>
</tr>
<tr>
<td>Overseas</td>
<td>94.0</td>
<td>118.1</td>
<td>+24.1</td>
</tr>
<tr>
<td>Tamiflu</td>
<td>16.9</td>
<td>5.6</td>
<td>-11.3</td>
</tr>
<tr>
<td>Royalties and other operating income (ROOI)</td>
<td>34.9</td>
<td>43.0</td>
<td>+8.1</td>
</tr>
<tr>
<td><strong>Core Operating Profit</strong></td>
<td>103.2</td>
<td>108.0</td>
<td>+4.8</td>
</tr>
<tr>
<td><strong>Core EPS (yen)</strong></td>
<td>138.68</td>
<td>147.00</td>
<td>+8.32</td>
</tr>
</tbody>
</table>

* CAGR: compound annual growth rate (%). Based on an constant average exchange rate for 2015
Priority Agenda for 2018

Continuous creation of innovative engineered antibody projects and establishing the drug creation technology of middle molecule

- Initiated clinical trials for two antibody projects: 2018-2019
- Further progress in middle molecule drug discovery: select clinical drug candidate by the end of IBI 18

Secure development of growth-driver projects

- Regulatory filing for seven projects
  - emicizumab: hemophilia A without inhibitor (Japan, US, EU)
  - Tecentriq: three line extensions (RCC, BC, 1\textsuperscript{st} line NSCLC)
  - Actemra (systemic sclerosis), Avastin (RCC), Edirol (osteoporosis [China])

Strengthen the system for providing solutions and secure market penetration of new products

- Fastest product value maximization of four new products (Tecentriq, Alaglio, emicizumab, obinutuzumab) and Perjeta line extension (adjuvant BC)
- Emicizumab co-promotion in Europe
- FMI collaboration: contribute to PHC with cancer genomic medicine as the No.1 company in Oncology

RCC: renal cell carcinoma, BC: breast cancer, PHC: personalized healthcare
Tecentriq Launch and Immuno-Oncology Projects

- Approved for NSCLC (2nd line) in Jan. 2018
- Extension of overall survival was confirmed across patient groups regardless of PD-L1 progression in 2nd and 3rd line NSCLC (OAK study)
- Seven trials ongoing in lung cancer with different patient groups/combination therapies; eight trials ongoing in different cancer types

- Created by utilizing Chugai’s proprietary antibody engineering technology [TRAB]
- Designed to redirect T cells to tumor cells by bivalently binding to CD3 on T cells and GPC3 on tumor cells, and active T cells to kill tumor cells
- Overseas P1 study is being conducted by Chugai

- Bispecific antibody in 2:1 format, in-licensed from Roche
- Designed to simultaneously bind to CEA with two arms and CD3 with one arm to trigger T cell migration, activation and antitumor effect
- Chugai decided to conduct development in Japan
Governmental Activities in Genomic Medicine and the FMI Collaboration

1. **Governmental Activities in Genomic Medicine**
   - Taskforce to promote medical and other use of genomic information
   - Genomic medicine promotion council

2. **The 3rd Phase Basic Plan to Promote Cancer Control Programs**
   - Preparation for FMI collaboration

- **2015**
  - Government
  - Chugai

- **2016**
  - **2017**
    - Stated practical use of “gene panel testing” for cancer
      - regulatory approval and the NHI coverage by the end of 2018 (Report of Cancer Genomic Medicine Promotion Consortium Council)

- **2018**
  - Establish framework for the FMI collaboration

NHI: National health insurance
Contribute to Oncology through the FMI Collaboration

Committed to advance PHC with innovative medical products and services as the No.1 company in Oncology

**New “Subscription Business” to provide highly precise information service**

- Next generation sequencer detects 324 cancer related genes
- Companion diagnostics
- Complementary diagnostics with BM through gene profiling
- Ultimate consulting promotion Synergy with pharmaceutical business
- Accelerate drug development based on genetic information

**Improve patient access to appropriate treatment**

BM: biomarker
FY2017 Consolidated Financial Overview (IFRS based)

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President, CFO
Yoshio Itaya

February 1/2, 2018
Full Year Results Summary

- **Revenues: 534.2 billion yen (+42.4, +8.6% YoY)**
  - Domestic sales excl. Tamiflu: increase as growth of mainstay products exceeded impact of HIP revision (+8.7, +2.3%)
  - Overseas sales: growth of Alecensa export to Roche, etc. (+14.5, +18.2%)
  - Royalties and other operating income: increase in milestone income (+15.8, +82.7%)

- **Cost of sales / Operating expenses (Core basis)**
  - Cost of sales: the ratio to sales improved due to change in product mix, etc. (-1.5% points, from 52.2% to 50.7%)
  - Operating expenses: increase in marketing and distribution expenses, research and development expenses, and general and administration expenses, etc. (-13.6, +8.3%)

- **Profits**
  - IFRS results: operating profit 98.9 billion yen (+22.0, +28.6%)
    net income 73.5 billion yen (+19.1, +35.1%)
  - Core results: operating profit 103.2 billion yen (+22.6, +28.0%)
    net income 76.7 billion yen (+19.9, +35.0%)
  - Core EPS (JPY): 138.68 (+36.18, +35.3%)
### FY2017 Consolidated Financial Overview

#### IFRS and Core Results  Jan - Dec

<table>
<thead>
<tr>
<th>(Billion JPY)</th>
<th>IFRS results</th>
<th>Non-core items</th>
<th>Core results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>534.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>499.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royalties and other operating income</td>
<td>34.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-254.2</td>
<td>+1.2</td>
<td></td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>280.0</td>
<td>+1.2</td>
<td></td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td>-181.1</td>
<td>+4.0</td>
<td>-1.0</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>-72.8</td>
<td>+4.0</td>
<td>-1.0</td>
</tr>
<tr>
<td>Research and development</td>
<td>-92.9</td>
<td></td>
<td>+4.0</td>
</tr>
<tr>
<td>General and administration</td>
<td>-15.3</td>
<td></td>
<td>-1.0</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>98.9</td>
<td>+5.3</td>
<td>-1.0</td>
</tr>
<tr>
<td>Financing costs</td>
<td>-0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other financial income (expense)</td>
<td>-0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other expenses</td>
<td>-1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit before taxes</strong></td>
<td>97.0</td>
<td>+5.3</td>
<td>-1.0</td>
</tr>
<tr>
<td>Income taxes</td>
<td>-23.5</td>
<td>-1.4</td>
<td>+0.3</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>73.5</td>
<td>+3.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Chugai shareholders</td>
<td>72.7</td>
<td>+3.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Non-Core items

- **Intangible assets:**
  - Amortization of intangible assets  +1.3  
  - Impairment  +4.0  

- **Others**
  - Legal income and expenses  -1.0  

- **Core net income attributable to Chugai shareholders**  75.9

### Additional Information

- **Weighted average number of shares and equity securities in issue used to calculate diluted earnings per share:** 547

- **Core EPS:** 138.68
## Financial Overview

### Revenues

| Component                        | 2016     | 2017     | Growth
|----------------------------------|----------|----------|--------
| Revenues                         | 491.8    | 534.2    | +42.4  +8.6%
| vs. Revenues                     |          |          |        |
| Sales                            | 472.7    | 499.3    | +26.6  +5.6%
| excl. Tamiflu                    | 459.2    | 482.4    | +23.2  +5.1%
| Domestic                         | 379.7    | 388.4    | +8.7   +2.3%
| Export to Roche                  | 62.8     | 76.4     | +13.6  +21.7%
| Other overseas                   | 16.8     | 17.7     | +0.9   +5.4%
| Tamiflu                          | 13.5     | 16.9     | +3.4   +25.2%
| Ordinary                         | 12.0     | 11.9     | -0.1   -0.8%
| Govt. stockpiles, etc.           | 1.5      | 5.0      | +3.5   +233.3%
| Royalties and other operating income | 19.1  | 34.9     | +15.8  +82.7%

**Cost of sales**

| Component                        | 2016   | 2017   | Growth
|----------------------------------|--------|--------|--------
| Cost of sales                    | -246.7 | -252.9 | -6.2   +2.5%
| vs. Revenues                     |        |        |        |
| Gross profit                     | 245.0  | 281.3  | +36.3  +14.8%
| Operating expenses               | -164.5 | -178.1 | -13.6  +8.3%
| Operating profit                 | 80.6   | 103.2  | +22.6  +28.0%
| Financing costs                  | -0.1   | -0.1   | 0.0    0.0%
| Other financial income (expense) | 1.1    | -0.1   | -1.2   - |
| Other Expenses                   | -3.5   | -1.7   | +1.8   -51.4%
| Income taxes                     | -21.3  | -24.5  | -3.2   +15.0%
| Net income                       | 56.8   | 76.7   | +19.9  +35.0%
| EPS (JPY)                        | 102.50 | 138.68 | +36.18 +35.3%

### Market average exchange rate (JPY)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 CHF</td>
<td>110.46</td>
<td>113.90</td>
</tr>
<tr>
<td>1 EUR</td>
<td>120.42</td>
<td>126.39</td>
</tr>
<tr>
<td>1 USD</td>
<td>108.83</td>
<td>112.17</td>
</tr>
<tr>
<td>1 SGD</td>
<td>78.82</td>
<td>81.22</td>
</tr>
</tbody>
</table>

### Additional Comments
- **Royalties and other operating income**: +15.8 billion JPY
- **Increase in milestone income**:
- **Other financial income (expense)**: -1.2 billion JPY
- **Exchange gains/losses**: -0.3 billion JPY
- **Gains/Losses on derivatives** (Gains/Losses on foreign exchange forward contracts): +0.4 billion JPY
- **Gain on sales of securities for investment (previous year), etc.**: -1.3 billion JPY
- **Other Expenses**: +1.8 billion JPY
- **Settlement for transfer pricing taxation**
Year on Year

Sales (excl. Tamiflu)  Jan - Dec

Sales by Disease Area,
Year on Year Comparisons

(Billions of JPY)

2016 2017

Domestic 379.7 41.1

Bone and Joint 86.1 93.3

Renal Diseases 41.1 39.3

Overseas 79.5 94.0

32.2 29.9

86.1 93.3

+23.2, +5.1% 482.4

-1.0, -8.7%

-0.9, -9.9%

Oncology 220.3 225.9

+5.6, +2.5%

+8.7, +2.3%

Sales by Products,
Year on Year Changes

Alecensa (16.7) +4.8, +40.3%

Alecensa (overseas) (13.9) +10.2, +275.7%

Emicizumab (overseas) (3.1) +3.1, -

[Commencing export from Q2, 2017]

Actemra (33.1) +2.9, +9.6%

Edirol (29.6) +2.9, +10.9%

Bonviva (8.7) +1.4, +19.2%

Rituxan (33.4) +1.3, +4.0%

Avastin (93.1) +1.0, +1.1%

Cellcept (8.9) +1.0, +12.7%

HER2 Franchise *(55.2) +1.0, +1.8%

*) Details of HER2 franchise

Herceptin (33.6) -0.5, -1.5%

Perjeta (13.6) +1.7, +14.3%

Kadcyla (8.0) -0.3, -3.6%

*: Actual sales in FY2016, has been included in “Others” from FY2017 1Q results.
# Tamiflu Sales Trends

<table>
<thead>
<tr>
<th>(Billions of JPY)</th>
<th>FY2012</th>
<th>FY2013</th>
<th>FY2014</th>
<th>FY2015</th>
<th>FY2016</th>
<th>FY2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan-Jun</td>
<td>Jul-Dec</td>
<td>Jan-Jun</td>
<td>Jul-Dec</td>
<td>Jan-Jun</td>
<td>Jul-Dec</td>
</tr>
<tr>
<td>Ordinary</td>
<td>7.8</td>
<td>2.4</td>
<td>1.9</td>
<td>5.8</td>
<td>1.5</td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>10.2 (+4.8)</td>
<td>10.1 (-0.1)</td>
<td>12.9 (+2.8)</td>
<td>8.2 (-4.7)</td>
<td>12.0 (+3.8)</td>
<td>11.9 (-0.1)</td>
</tr>
<tr>
<td>Govt. Stockpiles etc.</td>
<td>0.4</td>
<td>0.8</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>1.9 (-1.4)</td>
<td>0.9 (-1.0)</td>
<td>0.2 (-0.7)</td>
<td>0.0 (-0.2)</td>
<td>1.5 (+1.5)</td>
<td>5.0 (+3.5)</td>
</tr>
<tr>
<td>Total</td>
<td>8.1</td>
<td>3.9</td>
<td>9.0</td>
<td>7.1</td>
<td>6.7</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>12.0 (+3.8)</td>
<td>11.0 (-1.0)</td>
<td>13.0 (+2.0)</td>
<td>8.2 (-4.8)</td>
<td>13.5 (+5.3)</td>
<td>16.9 (+3.4)</td>
</tr>
</tbody>
</table>

(1) Year on year

## Season

(from the second half of FY to the first half of the next FY)

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>9.1</td>
</tr>
<tr>
<td>2012</td>
<td>10.6</td>
</tr>
<tr>
<td>2013</td>
<td>9.0</td>
</tr>
<tr>
<td>2014</td>
<td>12.6</td>
</tr>
<tr>
<td>2015</td>
<td>8.7</td>
</tr>
<tr>
<td>2016</td>
<td>11.0</td>
</tr>
<tr>
<td>2017</td>
<td>-</td>
</tr>
</tbody>
</table>
FY2017 Consolidated Financial Overview

Year on Year (Core)

Operating Profit Jan - Dec

(Billion of JPY)

<table>
<thead>
<tr>
<th></th>
<th>2016 Jan - Dec</th>
<th>2017 Jan - Dec</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>491.8</td>
<td>534.2</td>
<td>+42.4</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-246.7</td>
<td>-252.9</td>
<td>-6.2</td>
</tr>
<tr>
<td>Gross profit</td>
<td>245.0</td>
<td>281.3</td>
<td>+36.3</td>
</tr>
<tr>
<td>of which</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>225.9</td>
<td>246.4</td>
<td>+20.5</td>
</tr>
<tr>
<td>Royalties, etc.</td>
<td>19.1</td>
<td>34.9</td>
<td>+15.8</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>-69.8</td>
<td>-72.8</td>
<td>-3.0</td>
</tr>
<tr>
<td>Research and development</td>
<td>-82.6</td>
<td>-88.9</td>
<td>-6.3</td>
</tr>
<tr>
<td>General and administration</td>
<td>-12.1</td>
<td>-16.3</td>
<td>-4.2</td>
</tr>
<tr>
<td>Operating profit</td>
<td>80.6</td>
<td>103.2</td>
<td>+22.6</td>
</tr>
</tbody>
</table>

Increase in gross profit from sales: +20.5
Increase in export to Roche and improvement of cost of sales ratio to sales due to change in product mix etc.
Increase in royalties and other operating income: +15.8
Increase in marketing and distribution expenses: -3.0
Increase in sales promotion activities, etc.
Increase in research and development expenses: -6.3
Progress of projects and reclassification of some expenses due to organizational changes, etc.
Increase in general and administration expenses, etc.: -4.2
Increase in various expenses, including corporate enterprise tax (pro forma standard taxation)
## Financial Overview Oct - Dec

### Year on Year (Core)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>125.2</td>
<td>134.5</td>
<td>+9.3</td>
</tr>
<tr>
<td>excl. Tamiflu</td>
<td>120.2</td>
<td>127.7</td>
<td>+7.5</td>
</tr>
<tr>
<td>Domestic</td>
<td>102.4</td>
<td>107.5</td>
<td>+5.1</td>
</tr>
<tr>
<td>Export to Roche</td>
<td>13.6</td>
<td>15.8</td>
<td>+2.2</td>
</tr>
<tr>
<td>Other overseas</td>
<td>4.1</td>
<td>4.5</td>
<td>+0.4</td>
</tr>
<tr>
<td>Tamiflu</td>
<td>5.0</td>
<td>6.6</td>
<td>+1.6</td>
</tr>
<tr>
<td>Ordinary</td>
<td>4.7</td>
<td>5.6</td>
<td>+0.9</td>
</tr>
<tr>
<td>Govt. stockpiles, etc.</td>
<td>0.3</td>
<td>1.2</td>
<td>+0.9</td>
</tr>
<tr>
<td>Royalties and other operating income</td>
<td>5.1</td>
<td>12.0</td>
<td>+6.9</td>
</tr>
</tbody>
</table>

| Cost of sales     | -63.8          | -73.3          | -3.5   |

### Gross profit

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>130.3</td>
<td>146.6</td>
<td>+16.3</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-63.8</td>
<td>-73.3</td>
<td>-3.5</td>
</tr>
</tbody>
</table>

### Operating profit

<table>
<thead>
<tr>
<th>Operating profit</th>
<th>2016 Oct - Dec</th>
<th>2017 Oct - Dec</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financing costs</td>
<td>-0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Other financial income (expense)</td>
<td>0.6</td>
<td>0.1</td>
<td>-0.5</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>-3.5</td>
<td>-0.6</td>
<td>+2.9</td>
</tr>
<tr>
<td>Income taxes</td>
<td>-5.6</td>
<td>-6.9</td>
<td>-1.3</td>
</tr>
</tbody>
</table>

### Net income

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS (JPY)</td>
<td>30.88</td>
<td>30.88</td>
<td>+8.31</td>
</tr>
</tbody>
</table>

### Cost of sales ratio vs. Sales

- **2016 Oct - Dec**: 49.0%
- **2017 Oct - Dec**: 49.9%
- **Growth**: +5.5%

### Market average exchange rate for the period of Oct - Dec

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1CHF</td>
<td>109.22</td>
<td>114.41</td>
</tr>
<tr>
<td>1EUR</td>
<td>117.91</td>
<td>132.93</td>
</tr>
<tr>
<td>1USD</td>
<td>109.30</td>
<td>112.89</td>
</tr>
<tr>
<td>1SGD</td>
<td>77.55</td>
<td>83.38</td>
</tr>
</tbody>
</table>
## Financial Overview Jan - Dec

<table>
<thead>
<tr>
<th>(Billions of JPY)</th>
<th>2017 Jan - Dec</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Forecast</td>
<td>Actual</td>
<td>+/-</td>
<td>Achievement</td>
<td></td>
</tr>
<tr>
<td>Revenues</td>
<td>520.5</td>
<td>534.2</td>
<td>+13.7</td>
<td>102.6%</td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>490.4</td>
<td>499.3</td>
<td>+8.9</td>
<td>101.8%</td>
<td></td>
</tr>
<tr>
<td>excl. Tamiflu</td>
<td>482.2</td>
<td>482.4</td>
<td>+0.2</td>
<td>100.0%</td>
<td></td>
</tr>
<tr>
<td>Domestic</td>
<td>393.9</td>
<td>388.4</td>
<td>-5.5</td>
<td>98.6%</td>
<td></td>
</tr>
<tr>
<td>Export to Roche *</td>
<td>70.5</td>
<td>76.4</td>
<td>+5.9</td>
<td>108.4%</td>
<td></td>
</tr>
<tr>
<td>Other overseas</td>
<td>17.8</td>
<td>17.7</td>
<td>-0.1</td>
<td>99.4%</td>
<td></td>
</tr>
<tr>
<td>Tamiflu</td>
<td>8.2</td>
<td>16.9</td>
<td>+8.7</td>
<td>206.1%</td>
<td></td>
</tr>
<tr>
<td>Royalties and other operating income</td>
<td>30.0</td>
<td>34.9</td>
<td>+4.9</td>
<td>116.3%</td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-252.0</td>
<td>-252.9</td>
<td>-0.9</td>
<td>100.4%</td>
<td></td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td><strong>268.5</strong></td>
<td><strong>281.3</strong></td>
<td><strong>+12.8</strong></td>
<td><strong>104.8%</strong></td>
<td></td>
</tr>
<tr>
<td>Operating expenses</td>
<td>-176.5</td>
<td>-178.1</td>
<td>-1.6</td>
<td>100.9%</td>
<td></td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td><strong>92.0</strong></td>
<td><strong>103.2</strong></td>
<td><strong>+11.2</strong></td>
<td><strong>112.2%</strong></td>
<td></td>
</tr>
<tr>
<td>EPS (JPY)</td>
<td>124.11</td>
<td>138.68</td>
<td>+14.57</td>
<td>111.7%</td>
<td></td>
</tr>
</tbody>
</table>

### Cost of sales ratio vs. Sales

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan – Dec</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assumption</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actual *</td>
<td>51.4%</td>
<td>50.7%</td>
</tr>
</tbody>
</table>

### Exchange rate (JPY)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1CHF</td>
<td>106.00</td>
<td>113.90</td>
</tr>
<tr>
<td>1EUR</td>
<td>122.00</td>
<td>126.39</td>
</tr>
<tr>
<td>1USD</td>
<td>115.00</td>
<td>112.17</td>
</tr>
<tr>
<td>1SGD</td>
<td>80.00</td>
<td>81.22</td>
</tr>
</tbody>
</table>


* Market average exchange rate for the period of Jan – Dec.
### Sales Progress (excl. Tamiflu) Jan - Dec

(Billions of JPY) Sales by Disease Area, Actual vs. Forecast

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>2017 Jan - Dec</th>
<th>2017 Forecast</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Domestic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>230.0</td>
<td>225.9</td>
<td>-4.1, -1.8%</td>
</tr>
<tr>
<td>Renal Diseases</td>
<td>39.0</td>
<td>39.3</td>
<td>+0.3, +0.8%</td>
</tr>
<tr>
<td>Bone and Joint</td>
<td>94.5</td>
<td>93.3</td>
<td>-1.2, -1.3%</td>
</tr>
<tr>
<td>Overseas</td>
<td>88.4</td>
<td>94.0</td>
<td>+5.6, +6.3%</td>
</tr>
<tr>
<td>Others *</td>
<td>30.3</td>
<td>29.9</td>
<td>-0.4, -1.3%</td>
</tr>
<tr>
<td><strong>Total Domestic</strong></td>
<td>388.4</td>
<td>393.9</td>
<td>-5.5, -1.4%</td>
</tr>
<tr>
<td><strong>Overseas</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>230.0</td>
<td>229.9</td>
<td>-0.4, -0.1%</td>
</tr>
<tr>
<td>Renal Diseases</td>
<td>39.0</td>
<td>39.2</td>
<td>+0.3, +0.8%</td>
</tr>
<tr>
<td>Bone and Joint</td>
<td>94.5</td>
<td>93.8</td>
<td>-1.2, -1.3%</td>
</tr>
<tr>
<td>Overseas</td>
<td>88.4</td>
<td>94.0</td>
<td>+5.6, +6.3%</td>
</tr>
<tr>
<td>Others *</td>
<td>30.3</td>
<td>29.9</td>
<td>-0.4, -1.3%</td>
</tr>
<tr>
<td><strong>Total Overseas</strong></td>
<td>388.4</td>
<td>394.0</td>
<td>+1.4, +0.8%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>482.2</td>
<td>482.4</td>
<td>+0.2, +0.0%</td>
</tr>
</tbody>
</table>

### Sales by Products, Actual vs. Forecast

- **HER2 Franchise (*)**
  - 2017 Jan - Dec Actual: 94.0, -2.3, -4.0%
  - Forecast: 95.2
  - Overseas: 55.2
  - Domestic: 39.0

- **Alecensa**
  - Overseas: 13.9
  - Domestic: 16.7

- **Actemra**
  - Overseas: 60.9
  - Domestic: 33.1

- **Neutrogin**
  - Overseas: 12.3

- **Tarceva**
  - Overseas: 10.5

- **Xeloda**
  - Overseas: 12.2

- **Mircera**
  - Overseas: 23.9

- **Oxarol**
  - Overseas: 8.2

- **Herceptin**
  - Overseas: 33.6

- **Perjeta**
  - Overseas: 13.6

- **Kadoyla**
  - Overseas: 8.0

### Notes
- Sales in transplant, immunology, and infectious diseases area, which was disclosed separately until the end of FY2016, has been included in “Others” from FY2017 1Q results.
- Details of HER2 franchise are provided in a separate table.
- FY2017 Actual %: Achievement
Impact from Foreign Exchange

(Billions of JPY)

<table>
<thead>
<tr>
<th>FX impact Jan – Dec 2017 (FX impact vs. Assumption)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
</tr>
<tr>
<td>Sales</td>
</tr>
<tr>
<td>Royalties and other operating income</td>
</tr>
<tr>
<td>+3.2</td>
</tr>
<tr>
<td>+1.7</td>
</tr>
<tr>
<td>+1.5</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
</tr>
<tr>
<td>Cost of sales</td>
</tr>
<tr>
<td>Expenses</td>
</tr>
<tr>
<td>-1.4</td>
</tr>
<tr>
<td>-1.1</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
</tr>
<tr>
<td>+0.7</td>
</tr>
</tbody>
</table>

* Actual: market average exchange rate for the period of Jan - Dec
### Balance Sheet Items

**< Assets, Liabilities, and Net Assets >**

<table>
<thead>
<tr>
<th>(Billions of JPY)</th>
<th>2016 Dec</th>
<th>2017 Dec</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts receivable</td>
<td>140.7</td>
<td>148.5</td>
<td>+ 7.8</td>
</tr>
<tr>
<td>Inventories</td>
<td>185.4</td>
<td>169.1</td>
<td>- 16.3</td>
</tr>
<tr>
<td>Trade accounts payable</td>
<td>-42.5</td>
<td>-38.4</td>
<td>+ 4.1</td>
</tr>
<tr>
<td>Other net working capital *1</td>
<td>-25.2</td>
<td>-28.4</td>
<td>- 3.2</td>
</tr>
<tr>
<td><strong>Net working capital</strong></td>
<td>258.5</td>
<td>250.7</td>
<td>- 7.8</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>157.1</td>
<td>171.6</td>
<td>+ 14.5</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>19.3</td>
<td>21.1</td>
<td>+ 1.8</td>
</tr>
<tr>
<td>Other long-term assets - net *2</td>
<td>-3.7</td>
<td>-3.1</td>
<td>+ 0.6</td>
</tr>
<tr>
<td><strong>Long-term net operating assets</strong></td>
<td>172.7</td>
<td>189.5</td>
<td>+ 16.8</td>
</tr>
<tr>
<td><strong>Net operating assets</strong></td>
<td>431.1</td>
<td>440.2</td>
<td>+ 9.1</td>
</tr>
<tr>
<td>Debt</td>
<td>-0.6</td>
<td>-0.3</td>
<td>+ 0.3</td>
</tr>
<tr>
<td>Marketable securities</td>
<td>110.2</td>
<td>104.0</td>
<td>- 6.2</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>95.4</td>
<td>139.1</td>
<td>+ 43.7</td>
</tr>
<tr>
<td><strong>Net cash</strong></td>
<td>204.9</td>
<td>242.8</td>
<td>+ 37.9</td>
</tr>
<tr>
<td>Other non-operating assets - net *3</td>
<td>10.5</td>
<td>9.9</td>
<td>- 0.6</td>
</tr>
<tr>
<td><strong>Net non-operating assets</strong></td>
<td>215.4</td>
<td>252.7</td>
<td>+ 37.3</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>646.5</td>
<td>692.9</td>
<td>+ 46.4</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>806.3</td>
<td>852.5</td>
<td>+ 46.2</td>
</tr>
</tbody>
</table>

*1 Accrued receivable, accrued payable, accrued expenses, etc.

*2 Long-term prepaid expenses, long-term provisions, etc.

*3 Deferred tax assets, corporate income tax payable, etc.

### Change Explanation

- **Decrease in net working capital** -7.8

- **Increase in trade accounts receivable** +7.8

- **Increase in sales**

- **Decrease in inventories** -16.3

  - Impact from front-loaded purchases in the previous year, etc.

- **Decrease in trade accounts payable** +4.1

- **Decrease in other net working capital** -3.2

- **Increase in long-term net operating assets** +16.8

- **Increase in Property, plant and equipment** +14.5

  - Investment expenditure in production facilities, etc.

- **Increase in net cash** +37.9

- **Decrease in other non-operating assets** -0.6

- **Equity ratio attributable to Chugai shareholders** +1.1% pts.

<table>
<thead>
<tr>
<th>FX rate to the JPY (end of period)</th>
<th>2016 Dec</th>
<th>2017 Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>1CHF</td>
<td>113.94</td>
<td>115.35</td>
</tr>
<tr>
<td>1EUR</td>
<td>122.27</td>
<td>134.82</td>
</tr>
<tr>
<td>1USD</td>
<td>116.55</td>
<td>112.89</td>
</tr>
<tr>
<td>1SGD</td>
<td>80.47</td>
<td>84.39</td>
</tr>
</tbody>
</table>
The document provides a consolidated financial overview for the year ending December 2017 compared to the year ending December 2016.

**Net Cash (Billions of JPY)**

- **vs. 2016 Year End**
  - **2015 Dec**
    - **Net Cash**: 235.4
    - **Operating free cash flow**: +26.0
    - **Free cash flow**: +4.3
    - **Net Cash**: 2015 Dec

- **2016 Dec**
  - **Net Cash**: 242.8
  - **Operating free cash flow**: +91.0
  - **Free cash flow**: +64.7
  - **Net Cash**: 2016 Dec

- **2017 Dec**
  - **Net Cash**: 235.4
  - **Operating free cash flow**: +121.0
  - **Free cash flow**: +64.7
  - **Net Cash**: 2017 Dec

**Main investment for P.P.E**

- **Yokohama site**: Purchase of land for business
- **Ustunomiya**: High-mix low-volume production capability for pre-filled syringe form products
- **Ukima**: High-mix low-volume production of antibody API for initial commercial products
- **Fujieda**: Solid formulation manufacturing facility, etc.

**Corporate income tax payable, etc.**

- **Total investment**: +14.5
- **Total decrease in net working capital, etc.**: -26.2

**Dividends paid**

- **Net effect of currency translation on net cash, etc.**: -31.0

**Dividends paid**

- **Net effect of currency translation on net cash, etc.**: +4.1

**Transaction in own equity instruments + Net effect of currency translation on net cash**

- **Total investment**: +14.5
- **Total decrease in net working capital, etc.**: -26.2

**Net effect of currency transactions on net cash, etc.**

- **Main investment for P.P.E**
- **Corporate income tax payable, etc.**
- **Dividends paid**

**Main investment for P.P.E**

- **Yokohama site**: Purchase of land for business
- **Ustunomiya**: High-mix low-volume production capability for pre-filled syringe form products
- **Ukima**: High-mix low-volume production of antibody API for initial commercial products
- **Fujieda**: Solid formulation manufacturing facility, etc.

**Corporate income tax payable, etc.**

- **Total investment**: +14.5
- **Total decrease in net working capital, etc.**: -26.2

**Dividends paid**

- **Net effect of currency translation on net cash, etc.**: -31.0

**Dividends paid**

- **Net effect of currency translation on net cash, etc.**: +4.1

*1 Net effect of currency transactions on net cash, etc. = Transaction in own equity instruments + Net effect of currency translation on net cash

*2 It result from using different exchange rate types when consolidating overseas subsidiaries in financial statements, i.e. net cash using end of period exchange rate and free cash flow using average exchange rate. (Chugai defines this term based on International Accounting Standard (IAS) 7 and IAS 21)
Summary of Earnings Prospects for 2018

- **Revenues:**
  - Domestic sales excl. Tamiflu: despite continuous growth on a quantity basis, decrease due to impact of HIP revision
  - Overseas sales: overall growth mainly due to Actemra and Alecensa export to Roche
  - Royalties and other operating income: overall increase from the previous year due to ordinary income from Actemra, etc. and one-time income from transfer of long-listed products on HIP list

- **Cost of sales / Operating expenses (Core basis):**
  - Cost of sales: the ratio to sales will remain nearly the same as in the previous year
  - Operating expenses: overall increase mainly due to the increase of research and development expenses from progress of projects, etc.

- **Profits (Core basis):**
  - Despite decrease from impact of HIP revision or decrease in one-time income in the previous year, increase due to growth of mainstay products on a quantity basis and income from transfer of long-listed products on HIP list
### Forecast 2018 Jan - Dec

#### (Billions of JPY)

<table>
<thead>
<tr>
<th></th>
<th>Actual 2017 Jan - Dec</th>
<th>Forecast 2018 Jan - Dec</th>
<th>Growth vs. Revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>534.2</td>
<td>541.5</td>
<td>+7.3 (+1.4%)</td>
</tr>
</tbody>
</table>

|                  | vs. Revenues          | vs. Revenues          |
| Sales            | 499.3                 | 498.5                 | -0.8 (-0.2%)        |
| excl. Tamiflu    | 482.4                 | 492.9                 | +10.5 (+2.2%)       |
| Domestic         | 388.4                 | 374.8                 | -13.6 (-3.5%)       |
| Export to Roche  | 76.4                  | 99.6                  | +23.2 (+30.4%)      |
| Other overseas   | 17.7                  | 18.5                  | +0.8 (+4.5%)        |
| Tamiflu          | 16.9                  | 5.6                   | -11.3 (-66.9%)      |
| Ordinary         | 11.9                  | 5.0                   | -6.9 (-58.0%)       |
| Govt. stockpiles etc. | 5.0                  | 0.6                   | -4.4 (-88.0%)       |
| Royalties and other operating income | 34.9 | 43.0 | +8.1 (+23.2%) |

#### Cost of Sales ratio vs. Sales

<table>
<thead>
<tr>
<th></th>
<th>2017 Jan – Dec</th>
<th>2018 Jan – Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of sales ratio</td>
<td>50.7%</td>
<td>50.6%</td>
</tr>
</tbody>
</table>

#### Exchange rate (JPY)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1CHF</td>
<td>113.90</td>
<td>115.00</td>
</tr>
<tr>
<td>1EUR</td>
<td>126.39</td>
<td>133.00</td>
</tr>
<tr>
<td>1USD</td>
<td>112.17</td>
<td>111.00</td>
</tr>
<tr>
<td>1SGD</td>
<td>81.22</td>
<td>84.00</td>
</tr>
</tbody>
</table>

*Actual: market average exchange rate for the period of Jan – Dec.
**Movement of Operating Profit 2016 - 2018**

(Billions of JPY)

- **2016 Jan - Dec Actual**: 80.6
  - Gross profit +36.3
  - +22.6 (+28.0%)

- **2017 Jan - Dec Actual**: 103.2
  - Gross profit +8.2
  - +4.8 (+4.7%)

- **2018 Jan - Dec Forecast**: 108.0
  - Operating expenses
  - National Health Insurance drug price revision
  - Increase in sales volume, etc.
  - FX impact
  - One-time income
  - Royalties, etc.

**2018 Forecast (Core)**

FY2017 Consolidated Financial Overview
Sales (excl. Tamiflu) Forecast vs. 2017 Actual

(Billions of JPY)

2017 Jan – Dec Actual

Domestic 388.4

Overseas 94.0

Renal Diseases 39.3

Bone and Joint 93.3

Oncology 225.9

2018 Jan – Dec Forecast

Domestic 374.8

Overseas 118.1

Renal Diseases 35.3

Bone and Joint 97.1

Oncology 214.5

Sales by Disease Area, Year on Year Comparisons

+10.5, +2.2%

Actual 482.4

Forecast 492.9

Sales by Products, Year on Year Changes

+12.5, +89.9%

+12.1, +19.9%

+6.0, +35.9%

+2.1, +7.1%

+2.1, +6.3%

+1.2, +13.8%

+0.7, -

*) Details of HER2 franchise

Part of sales decrease from transfer of long-term listed products are included in the sales of disease areas of “Others” and “Oncology”.

*Part of sales decrease from transfer of long-term listed products are included in the sales of disease areas of “Others” and “Oncology”.

Herceptin (26.6) -7.0, -20.8%

Perjeta (14.6) +1.0, +7.4%

Kadcyla (8.3) +0.3, +3.8%

Rituxan (23.4) -10.0, -29.9%

HER2 Franchise *) (49.5)

Oxarol (5.8)

Avastin (92.0)

Emicizumab (overseas) (2.0)

Tarceva (9.8)

Bonviva (9.9)

Actemra (overseas) (73.0)

Actemra (35.2)

Alaglio (0.7)

%: Year-on-year percentage change

(): FY2018 forecast

-11.4, -5.0%

-4.0, -10.2%

+3.8, +4.1%

-1.1, -1.2%

-1.1, -35.5%

-0.7, -6.7%

-2.4, -29.3%

-10.3, -10.3%

-13.6, -3.5%

-5.7, -10.3%

-2.0, -6.7%

+12.5, +89.9%

+12.1, +19.9%

+6.0, +35.9%

+2.1, +7.1%

+2.1, +6.3%

+1.2, +13.8%

+0.7, -
Dividend Policy

Aiming to ensure stable profit for all shareholders and a consolidated dividend payout ratio of 50% on average to Core EPS, taking account of strategic funding needs and earnings prospects.

<table>
<thead>
<tr>
<th>Annual dividends per share (JPY)</th>
<th>Core payout ratio (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interim</strong></td>
<td><strong>End of FY</strong></td>
</tr>
<tr>
<td>Dividends for FY2017 (Plan)</td>
<td>29</td>
</tr>
<tr>
<td>Dividends for FY2018 (Forecast)</td>
<td>31</td>
</tr>
</tbody>
</table>

* Including special dividends

5-year average
5-year average (excl. special dividends)
Payout ratio to EPS

<table>
<thead>
<tr>
<th>Year</th>
<th>Regular dividends</th>
<th>Special dividends</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>17</td>
<td>6</td>
</tr>
<tr>
<td>2010</td>
<td>17</td>
<td>23</td>
</tr>
<tr>
<td>2011</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>2012</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>2013</td>
<td>23</td>
<td>22</td>
</tr>
<tr>
<td>2014</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>2015</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>2016</td>
<td>26</td>
<td>58</td>
</tr>
<tr>
<td>2017</td>
<td>33</td>
<td>52</td>
</tr>
<tr>
<td>2018</td>
<td>31</td>
<td>62</td>
</tr>
<tr>
<td>2019</td>
<td>31</td>
<td>62</td>
</tr>
</tbody>
</table>

40.0% 45.0% 50.0% 55.0%
Current Status / Plan for Major Capital Investments

- Building of state-of-the-art R&D site to create innovative new drug candidates
- Simultaneous development and quick launch of therapeutic antibodies, etc.
- Reduction of manufacturing costs for in-house products

CPR (Singapore): Accelerate creation of clinical candidates utilizing proprietary antibody technologies
2012-21: 476 million SGD / (225 million SGD), incl. capital investments of 61 million SGD / (49 million SGD)

Yokohama site: Purchase of land for business
2016-18: 43.4 billion JPY (4.8 billion JPY)

Utsunomiya Plant: Enhancement of high-mix low-volume production capability for pre-filled syringe form products (Installation of tray filler)
2013-18: 6.0 billion JPY (5.3 billion JPY)

Ukima Plant: Step 2, Enhancement of high-mix low-volume production of antibody API for initial commercial products (Expansion of production capability by construction of UK3)
2015-18: 37.2 billion JPY (24.3 billion JPY)

Fujieda Plant: Strengthening of solid formulation manufacturing facility, etc. (React to quick launch and steady supply)
2015-17: 6.0 billion JPY (5.7 billion JPY)
### Outline of Arrangements for Sales, Royalties, and Expenses of Three Products to Roche

<table>
<thead>
<tr>
<th></th>
<th>Actemra</th>
<th>Alecensa</th>
<th>Emicizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Export</strong></td>
<td>S: Export to Roche at the agreed supply price</td>
<td>S: Export to Roche at the agreed supply price</td>
<td>S: Export to Roche at the agreed supply price</td>
</tr>
<tr>
<td><strong>Co-Promotion, etc.</strong> (UK, Germany, France)</td>
<td>R: Profit Sharing</td>
<td>R: Royalty income</td>
<td>R: Profit Sharing</td>
</tr>
<tr>
<td></td>
<td>E: Cost sharing in agreed proportions</td>
<td>E: Receive promotion service fee from Roche (reimbursement of expenses)</td>
<td>E: Cost sharing in agreed proportions</td>
</tr>
<tr>
<td><strong>Other Region</strong></td>
<td>R: Royalty income</td>
<td>R: Royalty income</td>
<td>R: Royalty income</td>
</tr>
</tbody>
</table>

**Legends:**
- S: Sales
- R: Royalties and other operating income
- E: Expenses
Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.
Senior Vice President
Head of Project & Lifecycle Management Unit
Yasushi Ito

February 1/2, 2018
## Projects under Development (1) (as of Feb. 1, 2018)

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKI27 (Japan / overseas)</td>
<td>RG3502 / Kadcyla - breast cancer (adjuvant)</td>
<td>RG7446 / atezolizumab - NSCLC (adjuvant)</td>
<td>GA101 (RG7159) / obinutuzumab - follicular lymphoma</td>
</tr>
<tr>
<td></td>
<td>RG435 / Avastin - RCC</td>
<td>RG7440 / ipatasertib - prostate cancer</td>
<td>RG1273 / Perjeta - breast cancer (adjuvant)</td>
</tr>
<tr>
<td>RG7604 / taselisib</td>
<td>RG7596 / polatuzumab vedotin - DLBCL★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- solid tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GC33 (RG7686) / codrituzumab</td>
<td>- HCC★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERY974 (overseas)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KG7421 / cobimetinib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- solid tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Oncology

- **HCC**: hepatocellular carcinoma
- **NSCLC**: non-small cell lung cancer
- **SCLC**: small cell lung cancer
- **RCC**: renal cell carcinoma
- **DLBCL**: diffuse large B-cell lymphoma

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

Letters in orange: in-house projects

★: Projects with advances in stages since Oct. 25, 2017

★: Multinational study managed by Chugai
### Projects under Development (2) (as of Feb. 1, 2018)

<table>
<thead>
<tr>
<th>Phase</th>
<th>Autoimmune</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RG7845 - rheumatoid arthritis</td>
<td>RG7916 - spinal muscular atrophy</td>
<td>MRA / Actemra - systemic sclerosis</td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>SA237(RG6168) / satralizumab - neuromyelitis optica</td>
<td>RG1450 / gantenerumab - Alzheimer's disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RG7916 - spinal muscular atrophy</td>
<td>RG7412 / crenezumab - Alzheimer's disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RG6206 - DMD (PI/III)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Neurology | PCO371 (overseas) - hypoparathyroidism | RG3637 / lebrikizumab - IPF | ACE910 (RG6013) / emicizumab - hemophilia A (non-inhibitor) |       |
| Others | RG7716 - wAMD / DME | CIM331 / nemolizumab - pruritus in dialysis patients | ACE910 (RG6013) / emicizumab (Japan / EU) - hemophilia A (inhibitor) |       |
|         | URC102 (South Korea) - gout | SKY59 (RG6107) - paroxysmal nocturnal hemoglobinuria (PI/II) |       |       |

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

- **wAMD**: wet age-related macular degeneration
- **DME**: diabetic macular edema
- **IPF**: idiopathic pulmonary fibrosis
- **DMD**: Duchenne muscular dystrophy

**Letters in orange**: in-house projects
**★**: Projects with advances in stages since Oct. 25, 2017
**★**: Multinational study managed by Chugai

* Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]
Development Status (1)

**AF802 / Alecensa®**
Advanced ALK-positive NSCLC [1st line]
Approved in November 2017 (US)
Approved in December 2017 (EU)

**RG7446 / atezolizumab**
Unresectable advanced or recurrent NSCLC
Approved in January 2018
NSCLC [1st line] (B-FAST)
Started global Phase 2/3 study in November 2017

**ACE910 / emicizumab**
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors
Approved in November 2017 (US)
Recommendation for approval granted in January 2018 (EU)
Development Status (2)

**RG7440 / ipatasertib**
- Triple negative breast cancer
- Started global Phase 3 study in January 2018

**RG7596 / polatuzumab vedotin**
- Diffuse large B-cell lymphoma
- Started global Phase 3 study in November 2017

**RG7916 (SMN2 splicing modifier)**
- Spinal muscular atrophy
- Started global Phase 2 study in November 2017
Development Status (3)

**RG6206 (Anti-myostatin adnectin)**
- Duchenne muscular dystrophy
- Started global Phase 2/3 study in November 2017

**RG7802 (Anti-CEA/CD3 bispecific antibody(CEA-TCB))**
- Solid tumors
- Decided to start development

**RG1273 / Perjeta®**
- Gastric cancer
- Development discontinued
Other Progress

Alaglio® divided granules 1.5g (photodynamic diagnostic agent)
Diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection
Launched in December 2017

CIM331 / nemolizumab
Atopic dermatitis
Phase 3 study started by Maruho in November 2017 (Japan)
Results of Clinical Trials / Conference (1)

RG7446 / atezoZilumab
NSCLC 1st line: global Phase 3 study (IMpower150)
- One of the primary endpoints, progression-free survival (PFS) was achieved in November 2017
  - Statistically significant improvement in PFS with the addition of atezoZilumab versus Avastin® + chemotherapy was demonstrated
- Detailed data of IMpower150 was presented at the European Society of Medical Oncology Immuno Oncology Congress in December 2017

RCC 1st line: global Phase 3 study (IMmotion151)
- One of the primary endpoints, PFS was achieved in December 2017
  - atezoZilumab + Avastin® showed statistically significant improvement in PFS versus sunitinib (PD-L1 expression ≥ 1%, Investigator’s assessment)
ACE910 / emicizumab hemophilia A

Non-inhibitor: global Phase 3 study (HAVEN 3)
- Primary endpoint was achieved in November 2017
  - A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis (weekly/biweekly dosing) compared to those receiving no prophylactic treatment

Every four weeks dosing: global Phase 3 study (HAVEN 4)
- Interim results were announced in December 2017
  - Clinically meaningful reduction in the number of bleeds after a median of 17 weeks of treatment

Data presentation at American Society of Hematology meeting
- Inhibitor: Long-term expansion data from global Phase 3 study (HAVEN 1)
- Pediatrics inhibitor: Long-term expansion data from global Phase 3 study (HAVEN 2)
- Every four weeks dosing: Pharmacokinetic data assessing the cohort from global Phase 3 study (HAVEN 4)
Results of Clinical Trials / Conference (3)

ED-71 / Edirol®

Osteoporosis: global Phase 3 study (China)
• Primary endpoint was achieved in November 2017
  ➢ Significantly increased the bone mineral density of osteoporosis patients compared with alfacalcidol
Duchenne Muscular Dystrophy (DMD) is a hereditary disorder with progressive muscle weakness and its major pathology is simultaneous degeneration, necrosis, regeneration of skeletal muscle cells due to the mutation of dystrophin gene.

Myostatin is a negative regulator of skeletal muscle mass and a member of TGF-β superfamily.

RG6206 is a recombinant protein with two anti-myostatin adnectin molecules binding to human IgG1 Fc fragment.

RG6206 weekly SC injection is hoped to show its therapeutic effect for DMD by increasing muscle mass associated with reduction of active free serum myostatin.

RG7802 (CEA-TCB) and its MoA

**Overview of Development Pipeline**

**CEA-TCB and Target**
CEA-TCB is a novel T cell bispecific (TCB) antibody being investigated for the treatment of carcinoembryonic antigen (CEA)-expressing solid tumours. CEA-TCB has the potential to work in a broad range of solid tumours as CEA is overexpressed in a variety of cancers, including colorectal cancer (CRC)\(^1\).

**Structure and MoA**
CEA-TCB uses a novel 2-to-1 molecular design. It is engineered to bind simultaneously with one arm to CD3 on T-cells and with two arms to CEA on tumour cells, bringing T-cells into close proximity to the cancer cells. This leads to T-cell activation and subsequent tumour cell killing\(^1\).

**Unmet Need**
CEA-TCB-mediated T cell recruitment (and/or intra-tumour T cell expansion) may convert non-inflamed tumours into highly-inflamed tumours\(^1\), which may yield efficacy in tumour types not responsive to current cancer immunotherapies.

**Rationale for Combination**
Preclinical data indicate that CEA-TCB treatment leads to up-regulation of PD-L1 on tumour cells\(^2\), providing rationale to explore efficacy of CEA-TCB in combination with aPDL1 therapy.

---

References:
Projected Submissions (Post PoC NMEs and Products)

Overview of Development Pipeline

NME line extension

- in-house
- in-licensed

NSCLC: non-small cell lung cancer
RCC: renal cell carcinoma
SCLC: small cell lung cancer
MIUC: muscle invasive urothelial carcinoma
IPF: idiopathic pulmonary fibrosis
DLBCL: diffuse large B-cell lymphoma

Filed

- emicizumab (ACE910/RG6013) Hemophilia A (inhibitor) (Japan, EU)
- AVASTIN (RG435) RCC
- atezolizumab (RG7446) Breast Cancer
- emicizumab (ACE910/RG6013) Hemophilia A (non-inhibitor)
- satralizumab (SA237/RG6168) Neuromyelitis Optica
- SUVENYL (NRD101) Knee Osteoarthritis/Shoulder Periarthritis (China)
- atezolizumab (RG7446) RCC (adjuvant)
- atezolizumab (RG7446) MIUC (adjuvant)
- polatuzumab vedotin (RG7596) DLBCL
- Ediol (ED-71) Osteoporosis (China)
- atezolizumab (RG7446) SCLC
- atezolizumab (RG7446) NSCLC (adjuvant)

2017

- emicizumab (ACE910/RG6013) Hemophilia A (inhibitor) (Japan, EU)
- atezolizumab (RG7446) Breast Cancer
- obinutuzumab (GA101/RG7159) Follicular Lymphoma
- PERJETA (RG1273) Breast Cancer (adjuvant)

2018

- atezolizumab (RG7446) RCC
- ACTEMRA (MRA) Systemic Sclerosis
- polatuzumab vedotin (RG7596) DLBCL

2019

- satralizumab (SA237/RG6168) Neuromyelitis Optica
- SUVENYL (NRD101) Knee Osteoarthritis/Shoulder Periarthritis (China)
- atezolizumab (RG7446) RCC (adjuvant)
- atezolizumab (RG7446) MIUC (adjuvant)
- polatuzumab vedotin (RG7596) DLBCL

2020 and beyond

- lebrikizumab (RG3637) IPF
- atezolizumab (RG7446) Prostate Cancer
- creneuzumab (RG7412) Alzheimer’s Disease
- gantenerumab (RG1450) Alzheimer’s Disease
- atezolizumab (RG7446) MIUC (adjuvant)
- polatuzumab vedotin (RG7596) DLBCL
- atezolizumab (RG7446) Ovarian Cancer
- atezolizumab (RG7446) Prostate Cancer

*Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]
Updates on the Development Requests for Unapproved Drugs/Indications

Review Committee of Development Requests for Unapproved Drugs/Indication

- 1st round requests: all approved (ten indications, including additional dosages and administrations, of eight products)
- 2nd round requests: all approved (three indications of three products)
- 3rd round requests: requests were made for three indications of three products and two of them were approved

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Current Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin®</td>
<td>Additional dosage and administration for ovarian cancer</td>
<td>Submitted company opinion and waiting for evaluation by the committee</td>
</tr>
</tbody>
</table>

- 4th round requests: requests were made for two indications of two products and one of them was approved

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Current Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xeloda®</td>
<td>Neuroendocrine tumor</td>
<td>Submitted company opinion and waiting for evaluation by the committee</td>
</tr>
</tbody>
</table>
Contacts: Corporate Communications Dept.

Media Relations Group
Tel: +81 (0)3-3273-0881  Fax: +81 (0)3-3281-6607
e-mail: pr@chugai-pharm.co.jp
Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Chisato Miyoshi, Yayoi Yamada

Investor Relations Group
Tel: +81 (0)3-3273-0554  Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp
Toshiya Sasai, Takayuki Sakurai, Tomoko Shimizu, Tomoyuki Shimamura